MAP2K7 and neoplasm: Sorafenib, a multi-target inhibitor that targets the vascular endothelial growth factor receptor (VEGFR)/platelet-derived growth factor (PDGFR) pathway in tumor vasculature and the RAF/MEK/ERK pathway in tumor cells, has been widely used in the treatment of advanced liver cancer and renal cancer 58-60.